Close menu

Geneva, Switzerland, May 3, 2023 – 8:00am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of COVID-19, (PASC, post-COVID or Long-COVID), announced today the publication in the leading open science journal iScience from “Cell Press” of the new results from the collaboration between GeNeuro and the CIRI, Centre International de Recherche en Infectiologie, in Lyon, France, on the link between SARS-CoV-2 and the pathogenic HERV-W proinflammatory envelope protein (W-ENV).


Read the press release

More information